drugset / Trial / NCT04780529
CART Therapy in Digestive System Tumors
Unknown
20 enrolled
Innovative Cellular Therapeutics Co., Ltd.
Anhui Provincial Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric junction. Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.
Timeline
- Start
- 2021-03
- Primary completion
- 2022-04
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gucy2c cart cells | Cell therapy | — | Other |